Transcode Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
Transcode Therapeutics Stock-Based Compensation Growth & History (RNAZ)
Transcode Therapeutics's stock-based compensation was $485,428 for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $485,428 | −$1.2M | −71.45% |
| 2024 | 2024-12-31 | $1.7M | $663,110 | +63.95% |
| 2023 | 2023-12-31 | $1.0M | $641,560 | +162.29% |
| 2022 | 2022-12-31 | $395,329 | $209,333 | +112.55% |
| 2021 | 2021-12-31 | $185,996 | $140,552 | +309.29% |
| 2020 | 2020-12-31 | $45,444 | — | — |
Transcode Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0 | −$131,510 | — |
| Q1 2026 | 2026-03-31 | $0 | −$157,729 | — |
| Q4 2025 | 2025-12-31 | $61,865 | −$106,905 | −63.34% |
| Q3 2025 | 2025-09-30 | $134,324 | −$70,158 | −34.31% |
| Q2 2025 | 2025-06-30 | $131,510 | −$1.0M | −88.50% |
| Q1 2025 | 2025-03-31 | $157,729 | −$25,423 | −13.88% |
| Q4 2024 | 2024-12-31 | $168,770 | −$141,544 | −45.61% |
| Q3 2024 | 2024-09-30 | $204,482 | −$187,849 | −47.88% |
| Q2 2024 | 2024-06-30 | $1.1M | $968,111 | +551.68% |
| Q1 2024 | 2024-03-31 | $183,152 | $24,392 | +15.36% |
| Q4 2023 | 2023-12-31 | $310,314 | $179,759 | +137.69% |
| Q3 2023 | 2023-09-30 | $392,331 | $286,729 | +271.52% |
| Q2 2023 | 2023-06-30 | $175,484 | $76,885 | +77.98% |
| Q1 2023 | 2023-03-31 | $158,760 | $98,187 | +162.10% |
| Q4 2022 | 2022-12-31 | $130,555 | $91,555 | +234.76% |
| Q3 2022 | 2022-09-30 | $105,602 | $41,551 | +64.87% |
| Q2 2022 | 2022-06-30 | $98,599 | $64,085 | +185.68% |
| Q1 2022 | 2022-03-31 | $60,573 | $12,142 | +25.07% |
| Q4 2021 | 2021-12-31 | $39,000 | — | — |
| Q3 2021 | 2021-09-30 | $64,051 | $32,668 | +104.09% |
| Q2 2021 | 2021-06-30 | $34,514 | — | — |
| Q1 2021 | 2021-03-31 | $48,431 | — | — |
| Q3 2020 | 2020-09-30 | $31,383 | — | — |
Transcode Therapeutics stock-based compensation trends
Over the last five fiscal years, Transcode Therapeutics's stock-based compensation increased from $45,444 to $485,428, a change of $439,984. The latest reported quarter, Q2 2026, shows $0.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗